134 related articles for article (PubMed ID: 34806333)
21. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
[TBL] [Abstract][Full Text] [Related]
22. Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.
Chessari G; Hardcastle IR; Ahn JS; Anil B; Anscombe E; Bawn RH; Bevan LD; Blackburn TJ; Buck I; Cano C; Carbain B; Castro J; Cons B; Cully SJ; Endicott JA; Fazal L; Golding BT; Griffin RJ; Haggerty K; Harnor SJ; Hearn K; Hobson S; Holvey RS; Howard S; Jennings CE; Johnson CN; Lunec J; Miller DC; Newell DR; Noble MEM; Reeks J; Revill CH; Riedinger C; St Denis JD; Tamanini E; Thomas H; Thompson NT; Vinković M; Wedge SR; Williams PA; Wilsher NE; Zhang B; Zhao Y
J Med Chem; 2021 Apr; 64(7):4071-4088. PubMed ID: 33761253
[TBL] [Abstract][Full Text] [Related]
23. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
Shangary S; Ding K; Qiu S; Nikolovska-Coleska Z; Bauer JA; Liu M; Wang G; Lu Y; McEachern D; Bernard D; Bradford CR; Carey TE; Wang S
Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
[TBL] [Abstract][Full Text] [Related]
24. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
25. Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
Brandão P; Loureiro JB; Carvalho S; Hamadou MH; Cravo S; Moreira J; Pereira D; Palmeira A; Pinto M; Saraiva L; Cidade H
Eur J Med Chem; 2018 Aug; 156():711-721. PubMed ID: 30041135
[TBL] [Abstract][Full Text] [Related]
26. Proposing novel MDM2 inhibitors: Combined physics-driven high-throughput virtual screening and in vitro studies.
Aydin G; Paksoy MN; Orhan MD; Avsar T; Yurtsever M; Durdagi S
Chem Biol Drug Des; 2020 Jul; 96(1):684-700. PubMed ID: 32691963
[TBL] [Abstract][Full Text] [Related]
27. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
[TBL] [Abstract][Full Text] [Related]
28. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
[TBL] [Abstract][Full Text] [Related]
29. A novel drug discovery strategy: mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways.
Zhuang C; Sheng C; Shin WS; Wu Y; Li J; Yao J; Dong G; Zhang W; Sham YY; Miao Z; Zhang W
Oncotarget; 2014 Nov; 5(21):10830-9. PubMed ID: 25350970
[TBL] [Abstract][Full Text] [Related]
30. An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors.
Tortorella P; Laghezza A; Durante M; Gomez-Monterrey I; Bertamino A; Campiglia P; Loiodice F; Daniele S; Martini C; Agamennone M
J Chem Inf Model; 2016 Jun; 56(6):1216-27. PubMed ID: 27269808
[TBL] [Abstract][Full Text] [Related]
31. Prospective virtual screening for novel p53-MDM2 inhibitors using ultrafast shape recognition.
Patil SP; Ballester PJ; Kerezsi CR
J Comput Aided Mol Des; 2014 Feb; 28(2):89-97. PubMed ID: 24554192
[TBL] [Abstract][Full Text] [Related]
32. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458
[TBL] [Abstract][Full Text] [Related]
33. Discovery of new low-molecular-weight p53-Mdmx disruptors and their anti-cancer activities.
Uesato S; Matsuura Y; Matsue S; Sumiyoshi T; Hirata Y; Takemoto S; Kawaratani Y; Yamai Y; Ishida K; Sasaki T; Enari M
Bioorg Med Chem; 2016 Apr; 24(8):1919-26. PubMed ID: 27010502
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological activation of the p53 pathway by a new compound CYZ2017 exerts anti-tumor effects.
Han Y; Ren Z; Wu Y; Chen Y; Cui Z; Zhu T; Ma M; Du Y; Dong S
Biochem Biophys Res Commun; 2020 Dec; 533(4):1069-1075. PubMed ID: 33012506
[TBL] [Abstract][Full Text] [Related]
35. Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
Neochoritis CG; Atmaj J; Twarda-Clapa A; Surmiak E; Skalniak L; Köhler LM; Muszak D; Kurpiewska K; Kalinowska-Tłuścik J; Beck B; Holak TA; Dömling A
Eur J Med Chem; 2019 Nov; 182():111588. PubMed ID: 31421630
[TBL] [Abstract][Full Text] [Related]
36.
Al-Ghabkari A; Narendran A
Cancer Biother Radiopharm; 2019 May; 34(4):252-257. PubMed ID: 30724592
[No Abstract] [Full Text] [Related]
37. Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.
Huang Y; Wolf S; Beck B; Köhler LM; Khoury K; Popowicz GM; Goda SK; Subklewe M; Twarda A; Holak TA; Dömling A
ACS Chem Biol; 2014 Mar; 9(3):802-11. PubMed ID: 24405416
[TBL] [Abstract][Full Text] [Related]
38. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
[TBL] [Abstract][Full Text] [Related]
39. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma.
Andrews A; Warner K; Rodriguez-Ramirez C; Pearson AT; Nör F; Zhang Z; Kerk S; Kulkarni A; Helman JI; Brenner JC; Wicha MS; Wang S; Nör JE
Clin Cancer Res; 2019 Mar; 25(5):1588-1600. PubMed ID: 30498096
[TBL] [Abstract][Full Text] [Related]
40. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
